Patents by Inventor Yinghui CHAI

Yinghui CHAI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11655231
    Abstract: The disclosure relates to etoricoxib solvates and a preparation method thereof. A solvent is a hydrogen bond donor solvent with a polarity value ?* ranging from 60 to 100 or a hydrogen bond acceptor solvent with a polarity value ?* ranging from 92 to 100. Solvents with a polarity value ?* within the above range all can form corresponding etoricoxib solvates with etoricoxib. The etoricoxib solvate can be prepared by cooling crystallization or suspension crystallization. A 1,2-propanediol solvate of etoricoxib and a dimethyl sulfoxide (DMSO) solvate of etoricoxib provided in the present disclosure have high thermal stability, unique crystal form, large size, concentrated distribution, and prominent flowability and is safe, pharmaceutically acceptable, and not easy to agglomerate. Compared with etoricoxib, the etoricoxib solvates exhibit significantly improved solubility.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: May 23, 2023
    Assignee: Tianjin University
    Inventors: Ying Bao, Feng Zhang, Peihua Liang, Baohong Hou, Chuang Xie, Ting Zhang, Yinghui Chai
  • Publication number: 20210300892
    Abstract: The disclosure relates to etoricoxib solvates and a preparation method thereof. A solvent is a hydrogen bond donor solvent with a polarity value ?* ranging from 60 to 100 or a hydrogen bond acceptor solvent with a polarity value ?* ranging from 92 to 100. Solvents with a polarity value ?* within the above range all can form corresponding etoricoxib solvates with etoricoxib. The etoricoxib solvate can be prepared by cooling crystallization or suspension crystallization. A 1,2-propanediol solvate of etoricoxib and a dimethyl sulfoxide (DMSO) solvate of etoricoxib provided in the present disclosure have high thermal stability, unique crystal form, large size, concentrated distribution, and prominent flowability and is safe, pharmaceutically acceptable, and not easy to agglomerate. Compared with etoricoxib, the etoricoxib solvates exhibit significantly improved solubility.
    Type: Application
    Filed: March 22, 2021
    Publication date: September 30, 2021
    Inventors: Ying BAO, Feng ZHANG, Peihua LIANG, Baohong HOU, Chuang XIE, Ting ZHANG, Yinghui CHAI